Cantargia ABCHIX:CANTAS 37 OCF Yield % is 29.63 as of Jun. 29, 2026, which is 73% above its 10-year median of 17.17. GuruFocus rates CHIX:CANTAS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Cantargia AB ranks better than 99.22% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cantargia AB OCF Yield % Related Terms
Cantargia AB OCF Yield % Historical Data
* Premium members only.
The historical data trend for Cantargia AB's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CANTAS vs VRTX, REGN, ALNY: OCF Yield % Comparison
For the Biotechnology subindustry, Cantargia AB's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantargia AB OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantargia AB's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Cantargia AB's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantargia AB (CHIX:CANTAS) has a OCF Yield % of 29.63 as of Jun. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cantargia AB and its competitors. This is 73% above median its historical median of 17.17. Over the past decade, Cantargia AB's OCF Yield % has ranged from 9.74 to 29.99. According to the industry distribution chart, Cantargia AB ranks #11 out of 1417 companies in the Biotechnology industry, placing it in the top 0.8%.
Is Cantargia AB's OCF Yield % too high?
Cantargia AB's current OCF Yield % of 29.63 is 73% above median its 10-year median of 17.17. Over the past 10 years, this metric has ranged from a low of 9.74 to a high of 29.99. Based on the distribution chart, Cantargia AB ranks #11 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cantargia AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #11 out of 1417 companies for OCF Yield %. This places Cantargia AB in the top 1% of its industry — outperforming the majority of peers. Historically, Cantargia AB's own OCF Yield % has ranged from 9.74 to 29.99 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cantargia AB and its competitors. Cantargia AB's current OCF Yield % is 29.63, which is 73% above median its own 10-year median of 17.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current OCF Yield % of 29.63. The current OCF Yield % is 29.63, which is 73% above median its 10-year median of 17.17. Cantargia AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current OCF Yield % is 29.63 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score
Get the complete analysis for CHIX:CANTAS
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CANTAS has been successfully added to your 
